CDK 4/6 inhibitors combined with radiotherapy: A review of literature

CDK 4/6 inhibitors combined with radiotherapy: A review of literature

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and abemaciclib were granted approval by the European Medicines Agency (EMA) between 2017 and 2018. They are currently prescribed in combination with hormone therapy to treat hormone receptor positive, HER2 negative...

Full description

Bibliographic Details
Main Authors: Claire Bosacki, Wafa Bouleftour, Sandrine Sotton, Alexis Vallard, Elisabeth Daguenet, Hamza Ouaz, Iohel Cojoracu, Dariush Moslemi, Mona Molekzadehmoghani, Nicolas Magné
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Radiotherapy
CDK4/6 inhibitors
Palbociclib
Ribociclib
Abemaciclib
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630820300999

Internet

http://www.sciencedirect.com/science/article/pii/S2405630820300999

Similar Items